University of Cambridge Team Reports Early Data on New Class of microRNA Inhibitors | GenomeWeb

Researchers from the University of Cambridge last month reported on the development of novel microRNA inhibitors they hope can be developed into a new class of therapeutic capable of knocking down the small, non-coding RNAs in a variety of tissues.

At this stage, however, the molecules have only been tested in vitro against a single miRNA, with future optimization and testing contingent on the investigators securing new grant funding for their work.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.

Clinicians look to fold non-medical data into algorithms to predict patients' health, the Wall Street Journal reports.

Connecticut's biotech investment is leading to the building of labs to house new startups, the Associated Press reports.

Craig Venter's Health Nucleus aims to change preventive medicine, according to the Robb Report.